Drugs that contain Besifloxacin Hydrochloride
1. Besivance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5447926 | BAUSCH AND LOMB | Quinolone carboxylic acid derivatives |
Apr, 2016
(8 years ago) | |
| US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6699492 | BAUSCH AND LOMB | Quinolone carboxylic acid compositions and related methods of treatment |
Mar, 2019
(5 years ago) | |
| US6685958 | BAUSCH AND LOMB | Quinolone carboxylic acid compositions and related methods of treatment |
Jun, 2021
(2 years ago) | |
| US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(5 years from now) | |
| US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(5 years from now) | |
| US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2014 |
NCE-1 date: 28 May, 2013
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC
More Information on Dosage
BESIVANCE family patents
